Imagion Biosystems announces the presentation “MagSense® Imaging: Early Detection of Cancer Through Targeted Imaging.”
See the presentation “MagSense® Imaging“.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal